BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VOXZOGO (Vosoritide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VOXZOGO (Vosoritide)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04554940-10775@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:VOXZOGO (Vosoritide): Phase 2 readout est. (NCT04554940)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 2\, Achondroplasia.\nStudy: A Clin
 ical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achond
 roplasia\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04554940
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02724228-10775@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:VOXZOGO (Vosoritide): Phase 2 readout est. (NCT02724228)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 2\, Achondroplasia.\nStudy: A Stud
 y to Evaluate Long-Term Safety\, Tolerability\, & Efficacy of BMN 111 in C
 hildren With Achondroplasia (ACH)\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/vosoritide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02724228
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126262-10775@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:VOXZOGO (Vosoritide): Phase 2 readout est. (NCT07126262)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 2\, Hypochondroplasia.\nStudy: A S
 tudy of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 
 0 to < 36 Months\nEstimated primary completion: 30 June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07126262
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845749-10775@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:VOXZOGO (Vosoritide): Phase 1/2 readout est. (NCT05845749)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 1/2.\nStudy: Safety and Efficacy o
 f Voxzogo for Growth Deficits in MPS IVA and VI\nEstimated primary complet
 ion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/vosoritide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05845749
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424018-10775@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:VOXZOGO (Vosoritide): Phase 3 readout est. (NCT03424018)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 3\, Achondroplasia.\nStudy: An Ext
 ension Study to Evaluate the Efficacy and Safety of BMN 111 in Children Wi
 th Achondroplasia\nEstimated primary completion: June 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03424018
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989947-10775@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20380531
DTEND;VALUE=DATE:20380601
SUMMARY:VOXZOGO (Vosoritide): Phase 2 readout est. (NCT03989947)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 2\, Achondroplasia.\nStudy: An Ext
 ension Study to Evaluate Safety and Efficacy of BMN 111 in Children With A
 chondroplasia\nEstimated primary completion: May 2038. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03989947
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073014-10775@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20441031
DTEND;VALUE=DATE:20441101
SUMMARY:VOXZOGO (Vosoritide): Phase 3 readout est. (NCT07073014)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 3\, Hypochondroplasia.\nStudy: Lon
 g-Term Extension Study of Vosoritide to Treat Children With Hypochondropla
 sia\nEstimated primary completion: October 2044. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07073014
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
